IS IT FLUVOXAMINE’S TURN TO GET THE SILENT TREATMENT?
francinerose.substack.com
In October, 2021 the Lancet published the much awaited results of the fluvoxamine arm of its ongoing investigation into repurposed drugs to treat COVID-19. The results were positive showing a reduction in hospitalization and mortality in favour of the intervention arm. Since then, there has been little movement at the station when it comes to publicity for the well-established and generic anti-depressant.
IS IT FLUVOXAMINE’S TURN TO GET THE SILENT TREATMENT?
IS IT FLUVOXAMINE’S TURN TO GET THE SILENT…
IS IT FLUVOXAMINE’S TURN TO GET THE SILENT TREATMENT?
In October, 2021 the Lancet published the much awaited results of the fluvoxamine arm of its ongoing investigation into repurposed drugs to treat COVID-19. The results were positive showing a reduction in hospitalization and mortality in favour of the intervention arm. Since then, there has been little movement at the station when it comes to publicity for the well-established and generic anti-depressant.